Evidence map›Paper›PMID 26990456›Full record

ArticleThe Prostate2016

Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.

Martine P Roudier, Brian R Winters, Ilsa Coleman, Hung-Ming Lam, Xiaotun Zhang, Roger Coleman, Lisly Chéry, Lawrence D True, Celestia S Higano, Bruce Montgomery and 8 more

Open access · greenAbstract read
In one paragraph

Article in The Prostate, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Martine P RoudierDepartment of Urology, University of Washington, Seattle, Washington.
Brian R WintersDepartment of Urology, University of Washington, Seattle, Washington.
Ilsa ColemanFred Hutchinson Cancer Research Center, Seattle, Washington.
Hung-Ming LamDepartment of Urology, University of Washington, Seattle, Washington.
Xiaotun ZhangDepartment of Urology, University of Washington, Seattle, Washington.
Roger ColemanFred Hutchinson Cancer Research Center, Seattle, Washington.
Lisly ChéryDepartment of Urology, University of Washington, Seattle, Washington.
Lawrence D TrueDepartment of Pathology, University of Washington, Seattle, Washington.
Celestia S HiganoDepartment of Medicine, University of Washington, Seattle, Washington.
Bruce MontgomeryDepartment of Medicine, University of Washington, Seattle, Washington.
Paul H LangeDepartment of Urology, University of Washington, Seattle, Washington.
Linda A SnyderJanssen Research and Development, LLC, Spring House, Pennsylvania.
Shiv SrivastavaUniformed Services University of the Health Sciences, Rockville, Maryland.
Eva CoreyDepartment of Urology, University of Washington, Seattle, Washington.
Robert L VessellaDepartment of Urology, University of Washington, Seattle, Washington.
Peter S NelsonFred Hutchinson Cancer Research Center, Seattle, Washington.
Aykut ÜrenGeorgetown University Medical Center, Washington, District of Columbia.
Colm MorrisseyDepartment of Urology, University of Washington, Seattle, Washington.
University of Washington · USFred Hutch Cancer Center · USGeorgetown University · USJanssen (United States) · USUniformed Services University of the Health Sciences · USUniversity of Macau · MO

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI John Kyung Lee · 2002 to 2026
$58.1M
Steroid Metabolism in Castration-Resistant Prostate CancerP01CA163227 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Steven P. Balk · 2013 to 2026
$25.0M
Transmembrane Proteases and Prostate CarcinogenesisP01CA085859 · NCI · UNIVERSITY OF WASHINGTON · PI VESSELLA, ROBERT LOUIS · 2002 to 2013
$21.2M
NCI NIH HHS P01 CA085859NCI NIH HHS P01 CA163227NCI NIH HHS P50 CA097186
6 · The paper itself

Abstract

backgroundThe TMPRSS2-ERG gene fusion is detected in approximately half of primary prostate cancers (PCa) yet the prognostic significance remains unclear. We hypothesized that ERG promotes the expression of common genes in primary PCa and metastatic castration-resistant PCa (CRPC), with the objective of identifying ERG-associated pathways, which may promote the transition from primary PCa to CRPC.

methodsWe constructed tissue microarrays (TMA) from 127 radical prostatectomy specimens, 20 LuCaP patient-derived xenografts (PDX), and 152 CRPC metastases obtained immediately at time of death. Nuclear ERG was assessed by immunohistochemistry (IHC). To characterize the molecular features of ERG-expressing PCa, a subset of IHC confirmed ERG+ or ERG- specimens including 11 radical prostatectomies, 20 LuCaP PDXs, and 45 CRPC metastases underwent gene expression analysis. Genes were ranked based on expression in primary PCa and CRPC. Common genes of interest were targeted for IHC analysis and expression compared with biochemical recurrence (BCR) status.

resultsIHC revealed that 43% of primary PCa, 35% of the LuCaP PDXs, and 18% of the CRPC metastases were ERG+ (12 of 48 patients [25%] had at least one ERG+ metastasis). Based on gene expression data and previous literature, two proteins involved in calcium signaling (NCALD, CACNA1D), a protein involved in inflammation (HLA-DMB), CD3 positive immune cells, and a novel ERG-associated protein, DCLK1 were evaluated in primary PCa and CRPC metastases. In ERG+ primary PCa, a weak association was seen with NCALD and CACNA1D protein expression. HLA-DMB association with ERG was decreased and CD3 cell number association with ERG was changed from positive to negative in CRPC metastases compared to primary PCa. DCLK1 was upregulated at the protein level in unpaired ERG+ primary PCa and CRPC metastases (P = 0.0013 and P < 0.0001, respectively). In primary PCa, ERG status or expression of targeted proteins was not associated with BCR-free survival. However, for primary PCa, ERG+DCLK1+ patients exhibited shorter time to BCR (P = 0.06) compared with ERG+DCLK1- patients.

conclusionsThis study examined ERG expression in primary PCa and CRPC. We have identified altered levels of inflammatory mediators associated with ERG expression. We determined expression of DCLK1 correlates with ERG expression and may play a role in primary PCa progression to metastatic CPRC. Prostate 76:810-822, 2016. © 2016 Wiley Periodicals, Inc.

Indexed as

Gene Expression Regulation, NeoplasticHumansMaleOncogene Proteins, FusionPrognosisProstateProstatectomyProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantTranscriptional Regulator ERGERG protein, humanOncogene Proteins, FusionTMPRSS2-ERG fusion protein, humanTranscriptional Regulator ERGCRPCDCLK1ERGmetastasisprostate cancer

Identifiers

PMID26990456
PMCPMC5589183
OpenAlexW2298285788

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.